COVID-19 vaccine developed by the University of Oxford will be completed by the end of November of early December, an official said.
University of Oxford joined hands with British Swedish firm Astrazeneca to make a COVID 19 vaccine. The phase III trial has already started in United States and Brazil.
The vaccine has shown promising results in the first phase of clinical human trial. The researchers said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. “We are seeing good immune response in almost everybody," said Dr Adrian Hill, director of the Jenner Institute at Oxford University.Under an agreement between Mexican and Argentine governments and drugmaker, AstraZeneca may start.